{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors with Pleural Spread or Recurrence"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Participants": {
        "score": 2,
        "evidence": "45 adult patients with TETs and pleural dissemination were enrolled from August 1, 2021, to February 29, 2024."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention involved S-HITOC with 25 mg/m\u00b2 doxorubicin and 50 mg/m\u00b2 cisplatin."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses the safety and efficacy of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy (S-HITOC) in this setting."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of treatment-related adverse events of grade \u22653, assessed perioperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Blinding": {
        "score": 0,
        "evidence": "No randomisation or blinding was applied."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "45 adult patients with TETs and pleural dissemination were enrolled from August 1, 2021, to February 29, 2024."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 45 patients, eight (17.8%) experienced grade \u22653 adverse events."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 82.8% and 100.0%, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "Of the 45 patients, eight (17.8%) experienced grade \u22653 adverse events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05446935."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}